HPLC vs mass spectrometry: what each section of a COA tells you

Research use only. This content is for laboratory research; not for human or veterinary use, diagnosis, or treatment.

A Certificate of Analysis (COA) is the document that accompanies each batch of research peptide and certifies that the vial contains what the label claims. At Re/Vida, every batch published at /calidad includes both orthogonal assays: high-performance liquid chromatography (HPLC) and mass spectrometry (MS). HPLC quantifies chromatographic purity; MS confirms molecular identity. Understanding what each technique measures—and what it does not—lets you assess peptide quality without relying on marketing claims.

Why a single assay is not enough

HPLC separates molecules by retention time on a chromatographic column; it measures the fraction of the main peak relative to total area. It reports percent purity but does not identify which molecule corresponds to that peak. Mass spectrometry ionizes the sample and measures the mass-to-charge ratio (m/z); it confirms that the observed mass matches the theoretical mass of the target peptide, but it does not quantify impurities accurately.

A supplier may report 98% purity by HPLC, but without accompanying MS there is no proof that the major peak is the correct peptide. Conversely, an MS with correct m/z but no HPLC does not reveal how much truncated synthesis, dimer, or residual salt accompanies the product. Both assays are necessary and complementary.

How to read an HPLC chromatogram in the certificate of analysis

The chromatogram is a two-dimensional graph: X-axis in minutes (retention time), Y-axis in arbitrary units of UV absorbance, typically at 214 nm or 220 nm where the peptide bond absorbs. Each peak represents a molecular population eluting from the column.

1. Identify the main peak: usually labeled with retention time (e.g., 12.34 min) and area percentage (e.g., 98.2%).
2. Check secondary peaks: these appear before or after the target peak; they represent truncated sequences, isomers, dimers, or salts. Each peak should display time and area percentage.
3. Verify the baseline: it should be flat before the first peak and after the last. An elevated or drifting baseline suggests unresolved co-eluting contaminants.
4. Confirm column and gradient: a complete COA specifies column type (e.g., C18, 4.6 × 250 mm, 5 µm) and mobile phase (water/acetonitrile + TFA). Method changes alter retention times and resolution.

HPLC purity is calculated as (target peak area / sum of all peak areas) × 100. A peptide with 97% purity contains approximately 3% impurities detectable by UV at that wavelength. Impurities without a UV chromophore (salts, residual water, TFA) are not captured in this percentage.

How to interpret the mass spectrometry spectrum

Mass spectrometry ionizes the peptide in the gas phase; ions are separated by mass-to-charge ratio (m/z) in an analyzer (quadrupole, time-of-flight, ion trap). The resulting spectrum shows peaks at m/z values that correspond to charge states of the peptide.

1. Calculate the expected molecular mass: sum the masses of each amino acid, subtract one water molecule for each peptide bond formed, add modifications (acetylation, cyclization, counterion if it is a salt).
2. Identify multiply charged ion peaks: peptides >1000 Da typically ionize with +2, +3, or more protons. If the theoretical molecular weight is 1200 Da, expect peaks near m/z 601 ([M+2H]²⁺) and m/z 401 ([M+3H]³⁺).
3. Verify concordance: the COA should list theoretical mass (calculated) and observed mass (experimental). A difference <0.1% is acceptable; discrepancies >1 Da suggest incorrect sequence, undeclared modification, or major contaminant.
4. Look for satellite peaks: these appear at +16 Da (methionine oxidation), +18 Da (hydration), −17 Da (loss of ammonia). Their presence indicates synthesis byproducts or degradation.

MS does not quantify minor impurities accurately because ionization efficiency varies between molecules. An intense peak in MS confirms identity but does not guarantee high purity; that is why HPLC and MS must be read together.

What purity does not tell you: endotoxins, sterility, and water content

Endotoxins are lipopolysaccharides from the cell wall of gram-negative bacteria; even at picogram-per-milligram concentrations they can activate immune responses in cell cultures or animal models ^[1]. The FDA sets limits of <5 EU/kg for clinical-use injectables; in preclinical research, the threshold varies by experimental design. A complete COA reports endotoxins in endotoxin units per milligram (EU/mg).

Water and residual TFA content affect the net mass of active peptide. A lyophilized powder may contain 5–10% adsorbed water and 5–15% counterion (acetate, hydrochloride, TFA). If the vial declares 5 mg of crude peptide, the net peptide content may be 4–4.5 mg. Serious suppliers report peptide content corrected for water and counterion.

Step-by-step process: from synthesis to complete COA

1. Solid-phase synthesis: the peptide is built amino acid by amino acid on resin; it is cleaved and precipitated.
2. Preparative HPLC purification: the crude peptide is injected into a reversed-phase column; the target peak is collected in a pure fraction.
3. Lyophilization: the purified fraction is frozen and sublimed under vacuum; the resulting powder is weighed and packaged.
4. Analytical HPLC: an aliquot of the batch is dissolved and injected into an analytical column; the system records the chromatogram and calculates purity.
5. Mass spectrometry: another aliquot is ionized (ESI or MALDI) and the m/z spectrum is compared to the theoretical mass.
6. LAL assay: sample is dissolved in pyrogen-free water and incubated with LAL reagent; gelation or colorimetric change indicates endotoxins.
7. COA generation: the laboratory compiles the results—purity, m/z, endotoxins, appearance, solubility—into a single document with batch number, manufacturing date, and retest date.

At Re/Vida, every COA published at /calidad includes HPLC chromatogram, MS spectrum, endotoxin level, and certification from an external ISO 17025-accredited laboratory when applicable. The COA batch number must match that printed on the vial; any discrepancy invalidates traceability.

How to verify the authenticity of a COA

A forged or generic COA (a single document for all batches) offers no real assurance. Signs of authenticity include:

• Unique batch number printed on every page of the COA, matching the vial label.
• Chromatogram and spectrum with analysis date, not reused stock graphics.
• Signature and seal of the analyst or external laboratory; ideally with ISO 17025 accreditation number.
• Readable metadata: column, HPLC method, MS type (ESI, MALDI), acquisition software.
• Declared retest range: stability of lyophilized peptides is typically 12–24 months at −20 °C; longer retest dates without accelerated-stability data are suspect.

Re/Vida archives batch COAs at /calidad with traceability QR. If a supplier refuses to share a COA before purchase or delivers documents without a batch number, traceability is nonexistent.

Detection limits and the false security of '99+ %'

HPLC-UV has a detection limit of ~0.1–0.5% area; impurities below that threshold do not appear on the chromatogram. A report of '99.5% purity' means no impurities >0.5% were detected, not that the peptide is absolutely pure. Orthogonal techniques (coupled HPLC-MS, capillary electrophoresis, amino-acid analysis) may reveal impurities that HPLC-UV does not resolve.

In addition, declared purity is valid only under the conditions of the method: specific column, gradient, temperature. Method changes can separate co-eluting peaks and lower apparent purity. That is why COAs must include a complete description of the analytical method.

Side-by-side comparison: HPLC vs MS in the certificate of analysis

The conceptual table below summarizes what each technique measures and does not measure:

• HPLC: quantifies chromatographic purity (%), detects impurities with UV chromophore, does not confirm molecular identity, does not detect salts or water.
• MS: confirms molecular identity (m/z vs theoretical), detects covalent modifications, poor quantification of impurities, does not measure endotoxins.
• LAL assay: quantifies bacterial endotoxins (EU/mg), does not measure purity or peptide identity.
• Karl Fischer or TGA: quantifies residual water (%), does not identify the peptide or organic impurities.

A robust COA delivers at least HPLC + MS; ideally it adds endotoxins and net peptide content. Without these four parameters, characterization is incomplete.

Integration into research workflow

When receiving a research peptide, the recommended protocol includes:

1. Verify batch-number match between vial, printed COA, and digital COA published online.
2. Check retest date; if expired, request updated stability COA or discard.
3. Confirm HPLC purity ≥95% (typical threshold for in-vitro studies; in vivo may require ≥98%) and MS mass within ±0.05% of theoretical value.
4. Check endotoxin level: for cell culture, <1 EU/mg is advisable; for rodent injection, <5 EU/mg is a common threshold.
5. Log batch, purity, date in the laboratory notebook; archive the COA with experiment data for full traceability.

Documenting batch and purity allows you to reproduce results and diagnose batch-to-batch variability in case of experimental discrepancies.

Frequently asked questions about COA interpretation

Can HPLC report 98% but MS show the wrong molecule?

Yes. A major peak in HPLC can correspond to a peptide with incorrect sequence, an isomer, or a degradation product if the retention time is similar. Only MS confirms molecular identity. Suppliers without accompanying MS may be selling a major impurity.

Why do some COAs report purity >99% and others ~95%?

Short peptides (<10 amino acids) and sequences without cysteine typically purify to >98% in a single HPLC step. Long, cyclic, or post-translationally modified peptides may require re-purification; 95–97% is standard commercial purity. Purity >99.5% is exceptional and costly; many in-vitro studies do not require that level.

What do I do if the COA does not list endotoxins?

Request an LAL assay from the supplier. If they refuse or lack capability, assume the batch may contain endotoxins >10 EU/mg, a level that interferes with most cell assays. For animal use or culture, unquantified endotoxins are a serious experimental risk ^[2].

Conclusion: two techniques, one quality narrative

HPLC and mass spectrometry do not compete; they complement. HPLC quantifies chromatographic purity accurately but does not identify; MS confirms molecular identity but does not quantify minor impurities. A Certificate of Analysis without both assays leaves blind spots that marketing can hide but the experiment will eventually reveal.

Re/Vida publishes both chromatograms—HPLC and MS—along with endotoxins and retest date at /calidad, because complete documentation is the only real substitute for blind trust. When the research peptide is the independent variable of the experiment, its characterization cannot be the hidden variable.